Brain tumor gene mapping project launches in Seattle

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 12
Volume 18
Issue 12

The Ivy Glioblastoma Atlas Project will track genetic mutations in glioblastoma multiforme and produce a free, online medical atlas. The Seattle-based project is a partnership between the Ben and Catherine Ivy Foundation, the Allen Institute for Brain Science, and the Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment at the Swedish Neuroscience Institute.

The Ivy Glioblastoma Atlas Project will track genetic mutations in glioblastoma multiforme and produce a free, online medical atlas. The Seattle-based project is a partnership between the Ben and Catherine Ivy Foundation, the Allen Institute for Brain Science, and the Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment at the Swedish Neuroscience Institute.

Research on the Glioblastoma Atlas Project (GAP) is slated for completion in 2013. The resulting atlas information will then be made available online for free use by the global medical and scientific communities.

GAP will target 1,000 genes, which were selected for study by a panel of physician scientists and medical professionals led by Greg Foltz, MD, co-director of the Ivy Center for Advanced Brain Tumor Treatment. Dr. Foltz will serve as the lead investigator on the atlas.

Articles in this issue
Cetuximab plus chemo boosts surgery in advanced colon ca
OB/GYN revises suggested age for cervical ca screening
Brain tumor gene mapping project launches in Seattle
PET timing guides radiation RX in lung ca
Experts take umbrage with federal panel change to age for mammo screening
Radiosurgery gains role for noncancer applications
New radiotracer shows early treatment response for patients with lung cancer
Addition of rituximab improves OS in chronic lymphocytic leukemia
Micromet scores multiple development deals
New agents for lymphoma take center stage
Vaccines plus screening could end cervical ca
Post-treatment pain remains clinically significant in breast cancer patients
Oncology dodges CMS worst case scenario
RCC adverse effects and symptoms: Kidney cancer specialists must meet new challenges
Classic phase II trials: Unable to meet the challenges in oncology, or an integral aspect of drug development?
Recent Videos
Shwetal Mehta, PhD, describes efforts regarding the development of protein degraders and antibody-drug conjugates in the neuro-oncology field.
Liquid biopsy tests may help determine the extent of activity among patients who receive a novel fourth-generation EGFR inhibitor for brain cancer.
Shwetal Mehta, PhD, highlights novel brain cancer drug development procedures in the clinical lab and pre-clinical arms of the Ivy Brain Tumor Center.
Raymond B. Mailhot, MD, MPH, discussed how radiation therapy can impact education and survivorship for pediatric survivors of brain tumors.
Significant results from a retrospective analysis of brain tumor survivor academic performance after radiotherapy emerged despite small sampling size.
Raymond B. Mailhot, MD, MPH, discussed methods for comparing academic performances of patients following radiation therapy with healthy control groups.
The act of asking for help is critical to finding mentors who can help one advance in the brain cancer field, according to Yoshie Umemura, MD.
Through multidisciplinary collaboration, Yoshie Umemura, MD, and colleagues were able to organize the Gliofocus trial in brain cancer relatively fast.
Yoshie Umemura, MD, discusses how multiple departments can positively impact a patient with brain cancer during their visit to a medical center.
Antibody-drug conjugates and small molecule inhibitors may show utility in the neuro-oncology field, according to Nader Sanai, MD.
Related Content
The approval marks Foundation Medicine’s first companion diagnostic indication to exclusively support pediatric patients with brain tumors.

FDA Approves FoundationOne CDx Diagnostic for Tovorafenib in Brain Tumors

Roman Fabbricatore
January 20th 2025
Article

The approval marks Foundation Medicine’s first companion diagnostic indication to exclusively support pediatric patients with brain tumors.

Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.

Conducting Early Phase Trials of Promising Treatments in Neuro-Oncology

Shwetal Mehta, PhD
January 27th 2025
Podcast

Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.

Developers have requested priority review status for dordaviprone as a treatment for patients with recurrent H3 K27M-mutated glioma.

FDA Receives NDA for Dordaviprone in Recurrent H3 K27M+ Glioma

Russ Conroy
January 2nd 2025
Article

Developers have requested priority review status for dordaviprone as a treatment for patients with recurrent H3 K27M-mutated glioma.

The only way forward in the brain cancer field is to be open to mentoring others, according to Yoshie Umemura, MD.

Forming Connections and Making a Difference in the Brain Cancer Field

Yoshie Umemura, MD
October 7th 2024
Podcast

The only way forward in the brain cancer field is to be open to mentoring others, according to Yoshie Umemura, MD.

Targeting axonal guidance dependencies in glioblastoma with ROBO1 CAR T cells

Targeting axonal guidance dependencies in glioblastoma with ROBO1 CAR T cells

American Society for Transplantation and Cellular Therapy
November 25th 2024
Article

Researchers at SickKids Hospital and McMaster University have developed a novel CAR T-cell therapy targeting ROBO1 for the treatment of recurrent glioblastoma.

Patients with newly diagnosed glioblastoma had improved survival when treated with TTFields plus temozolomide and pembrolizumab.

TTFields Plus Temozolomide/Pembrolizumab Controls Tumors in Glioblastoma

Ariana Pelosci
November 11th 2024
Article

Patients with newly diagnosed glioblastoma had improved survival when treated with TTFields plus temozolomide and pembrolizumab.